Literature DB >> 16985783

Medical and minimally invasive treatment of urinary incontinence.

J P Lavelle, S Teahan, D Y Kim, M B Chancellor.   

Abstract

Newer agents and procedures give urologists more options in treating patients who have urinary incontinence related to such etiologies as an ineffective sphincter, detrusor hypersensitivity, obstruction, or a combination of these. Abolition of the involuntary contractions characteristic of detrusor instability can be accomplished pharmacologically or surgically. First-line anticholinergic agents are tolterodine and oxybutynin XL, given orally. Alternatively, intravesical administration provides a high concentration of drug, such as capsaicin or resiniferatoxin, at the detrusor muscle level. However, this commits the patient to intermittent self-catheterization. Surgery is reserved for those who have failed prolonged trials of conservative therapies. For patients with intractable urge incontinence, urologists have the new technique of sacral nerve stimulation.

Entities:  

Year:  1999        PMID: 16985783      PMCID: PMC1476137     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  11 in total

1.  Double-blind, placebo-controlled, cross-over study of flavoxate in the treatment of idiopathic detrusor instability.

Authors:  C R Chapple; H Parkhouse; C Gardener; E J Milroy
Journal:  Br J Urol       Date:  1990-11

2.  Diagnostic evaluation of incontinence in patients with neurological disorders.

Authors:  M B Chancellor; J G Blaivas
Journal:  Compr Ther       Date:  1991-02

3.  Response to treatment of detrusor instability in relation to psychoneurotic status.

Authors:  K H Moore; J R Sutherst
Journal:  Br J Urol       Date:  1990-11

4.  Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin.

Authors:  S K Gupta; G Sathyan
Journal:  J Clin Pharmacol       Date:  1999-03       Impact factor: 3.126

5.  Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.

Authors:  R A Appell
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

6.  Obstruction following anti-incontinence procedures: diagnosis and treatment with transvaginal urethrolysis.

Authors:  V W Nitti; S Raz
Journal:  J Urol       Date:  1994-07       Impact factor: 7.450

7.  The value of urodynamic testing in stress urinary incontinence.

Authors:  E J McGuire; B Lytton; E I Kohorn; V Pepe
Journal:  J Urol       Date:  1980-08       Impact factor: 7.450

8.  The effect of flavoxate on uninhibited detrusor contractions and urinary incontinence in the elderly.

Authors:  R S Briggs; C M Castleden; M J Asher
Journal:  J Urol       Date:  1980-05       Impact factor: 7.450

9.  Pubovaginal sling procedure for stress incontinence.

Authors:  E J Mcguire; B Lytton
Journal:  J Urol       Date:  1978-01       Impact factor: 7.450

10.  Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.

Authors:  P Abrams; R Freeman; C Anderström; A Mattiasson
Journal:  Br J Urol       Date:  1998-06
View more
  1 in total

1.  Sacral nerve stimulation for the management of voiding dysfunction.

Authors:  A K Das; M D White; P A Longhurst
Journal:  Rev Urol       Date:  2000
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.